Back to top
more

Ascendis Pharma (ASND)

(Delayed Data from NSDQ)

$124.28 USD

124.28
974,853

-1.75 (-1.39%)

Updated Nov 14, 2024 04:00 PM ET

After-Market: $119.00 -5.28 (-4.25%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Ascendis Pharma A/S (ASND) Soars 8.5%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Ascendis Pharma A/S (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

The Zacks Analyst Blog Highlights bluebird, Oncternal Therapeutics, Avidity, Ascendis and Vertex Pharmaceuticals

by Zacks Equity Research

bluebird, Oncternal Therapeutics, Avidity, Ascendis and Vertex Pharmaceuticals are included in this Analyst Blog.

Biotech Stock Roundup: BLUE Announces Q4 Results, ONCT, ASND & RNA Fall on Updates

by Zacks Equity Research

Earnings and pipeline updates from bluebird bio (BLUE) and Avidity (RNA) are the key highlights for the biotech sector.

Ascendis (ASND) Down on Hypoparathyroidism Drug NDA Deficiencies

by Zacks Equity Research

The FDA identifies deficiencies in Ascendis' (ASND) regulatory filing for TransCon PTH in hypoparathyroidism. This might lead to an extended review timeline of the company's filing.

Omega Therapeutics, Inc. (OMGA) Moves 15.2% Higher: Will This Strength Last?

by Zacks Equity Research

Omega Therapeutics, Inc. (OMGA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Does Ascendis Pharma AS (ASND) Have the Potential to Rally 35% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 34.6% upside potential for Ascendis Pharma AS (ASND). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Elevance Health (ELV) Beat Q2 Earnings on Membership Growth?

by Zacks Equity Research

Elevance Health's (ELV) second-quarter results are likely to reflect improved Commercial Business operations, driven by the robust growth in risk-based areas.

Why Ascendis Pharma (ASND) Might Surprise This Earnings Season

by Zacks Equity Research

Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Encompass Health (EHC) is Down 2.4% Since Q1 Earnings Beat

by Zacks Equity Research

Encompass Health Corporation (EHC) looks to unveil eight additional de novo locations this year and increase its bed count.

Vermilion Energy (VET) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

A favorable commodity pricing scenario is likely to have aided Vermilion Energy's (VET) earnings in Q1.

    Teladoc (TDOC) Plunges 40.3% Since Q1 Earnings Beat: Here's Why

    by Zacks Equity Research

    Teladoc Health's (TDOC) bet on mental health service BetterHelp is likely to generate lower yield this year.

    Ring Energy (REI) to Report Q1 Earnings: What's in Store?

    by Zacks Equity Research

    A favorable commodity pricing scenario is likely to have aided Ring Energy's (REI) earnings in Q1.

    Aditi Saraogi headshot

    Should You Buy Ascendis Pharma (ASND) Ahead of Earnings?

    by Aditi Saraogi

    Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

    Ascendis Pharma AS (ASND) Surges 6.5%: Is This an Indication of Further Gains?

    by Zacks Equity Research

    Ascendis Pharma AS (ASND) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

    Pfizer's (PFE), OPKO's BLA for Somatrogon Gets CRL From FDA

    by Zacks Equity Research

    The FDA issues a Complete Response Letter to Pfizer (PFE) and OPKO Health's biologics license application for somatrogon to treat growth hormone deficiency in pediatric patients.

    Ascendis' (ASND) TransCon hGH Gets EU Nod for Pediatric GHD

    by Zacks Equity Research

    Ascendis Pharma (ASND) gets nod in Europe for TransCon hGH for the treatment of pediatric growth hormone deficiency.

      Ascendis (ASND) Gets Positive CHMP Opinion for GHD Drug Filing

      by Zacks Equity Research

      Ascendis Pharma (ASND) is seeking approval for TransCon hGH for the treatment of pediatric growth hormone deficiency in Europe.

      AstraZeneca (AZN) to Report Q3 Earnings: What's in the Cards?

      by Zacks Equity Research

      AstraZeneca's(AZN) third-quarter results are expected to reflect the impact of strong demand for new drugs. Investors are likely to focus on sales numbers of AstraZeneca's COVID-19 vaccine.

      Is a Beat in Store for BioNTech (BNTX) This Earnings Season?

      by Zacks Equity Research

      On BioNTech's (BNTX) third-quarter earnings call, investors' focus is expected to be on the sales performance of Comirnaty, its COVID-19 vaccine developed in partnership with Pfizer.

      Organon (OGN) to Report Q3 Earnings: What's in the Cards?

      by Zacks Equity Research

      Organon (OGN) is set to provide updates on its earnings and revenues when it reports third-quarter 2021 results.

      Ascendis (ASND) Seeks FDA Nod for New Immunotherapy Study

      by Zacks Equity Research

      Ascendis (ASND) plans to develop a sustained-release immunotherapy to treat advanced cancer developed using its TransCon platform.

      Ascendis (ASND) Rallies on First FDA-Approved Drug Skytrofa

      by Zacks Equity Research

      Ascendis' (ASND) Skytrofa gets FDA approval for treating growth failure in pediatric patients. The drug is also the first FDA-approved product in the company's portfolio.

      Is a Surprise Coming for Ascendis Pharma (ASND) This Earnings Season?

      by Zacks Equity Research

      Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

      Ascendis' (ASND) BLA for GHD Candidate Gets Review Extension

      by Zacks Equity Research

      Ascendis (ASND) is seeking approval for lonapegsomatropin as a potential treatment of pediatric growth hormone deficiency.

      New Strong Sell Stocks for January 14th

      by Zacks Equity Research

      Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.